Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Bilayer Therapeutics is raising $3,600,000.00 in new funding. Sources indicate as part of senior management President, Thomas Collet played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bilayer Therapeutics

Bilayer Therapeutics is developing a first-in-class therapeutic for constipation and other diseases of the colon (Irritable Bowel Syndrome, chronic idiopathic constipation, ulcerative colitis, Crohn’s Disease, hepatic encephalopathy, etc.).

To learn more about Bilayer Therapeutics, visit http://bilayer-therapeutics.com/

Contact:
Thomas Collet, President
734-358-9015

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved